ADMA Biologics plunges 45% on fraud allegations, channel stuffing claims
Multiple law firms investigate plasma-derived biotech after short seller report
ADMA Biologics shares have collapsed 45% over five trading sessions, wiping out approximately $1.6 billion in market value, after a short seller report alleged the company engaged in channel stuffing to artificially inflate revenue figures. The steep decline has triggered multiple securities fraud investigations from prominent law firms and prompted an analyst downgrade.
The stock, which traded around $14 before March 24, fell to $7.93 by March 26, continuing its slide to approximately $8.29 in recent trading. The sell-off began when Culper Research published a report on March 24 accusing the New Jersey-based biopharmaceutical company of orchestrating a channel stuffing scheme that allegedly inflated its 2025 revenue by approximately 20%, according to multiple law firm announcements.
Culper Research, which disclosed a short position in the stock, alleged that ADMA induced one of its two largest distributors to stock excess quantities of its flagship product ASCENIV by offering rebates and extended payment terms. The report claims that without these alleged practices, ADMA's revenue would have declined 3% in 2025 rather than showing the reported growth. Culper estimates that ASCENIV revenues are inflated by 40-76%.
The short seller highlighted several financial metrics it described as "textbook red flags." ADMA's Days Sales Outstanding (DSO), a measure of how quickly the company collects payments, ballooned from 43 days to 113 days in 2025. Additionally, the report noted that despite reporting $231 million in adjusted EBITDA, the company generated only $50 million in cash from operations—a substantial shortfall suggesting much of the reported revenue was not converting to actual cash.
Two distributors, BioCare and CuraScript, accounted for 73% of revenues and 87% of year-end receivables, creating significant concentration risk that Culper characterized as unusual for the industry.
ADMA Biologics categorically denied the allegations in a statement issued March 25, characterizing the Culper Research report as "misleading" and "premised on speculative assertions derived from unidentified and unreliable sources." The company stated the report contains "numerous misleading, false and inaccurate statements" and reiterated its commitment to adhering to SEC regulations and U.S. GAAP standards. ADMA said it was taking appropriate steps to review the assertions.
The allegations have prompted multiple shareholder rights law firms to launch investigations. Glancy Prongay & Rotter LLP, the Law Offices of Frank R. Cruz, BFA Law, and Pomerantz Law Firm have all announced they are investigating potential violations of federal securities laws on behalf of investors who purchased ADMA securities. Several firms issued alerts notifying investors of their investigations.
Cantor Fitzgerald downgraded ADMA's stock from "Overweight" to "Neutral" on March 26, reflecting growing uncertainty about the company's financial reporting and business practices. The downgrade came as the stock extended its losses, dropping an additional 16-17% that session after the initial 29% plunge over the previous two days.
ADMA Biologics, which develops, manufactures, and markets plasma-derived biologics for treating immune deficiencies and infectious diseases, had previously shown strong growth. The company's products include BIVIGAM and ASCENIV, both intravenous immune globulin therapies, and Nabi-HB for Hepatitis B exposure treatment. Before the sell-off, the stock had reached a 52-week high of $25.67.
The company's heavy institutional ownership—approximately 95% of shares—are held by institutional investors—amplifies the impact of the allegations. With 238 million shares outstanding and a market capitalization that has shrunk to roughly $2 billion, the stock remains highly volatile as investors await further clarification from the company or regulatory authorities.
The sharp decline represents a dramatic reversal for a company that had been viewed as a growth player in the biopharmaceutical space. ADMA had reported $510 million in trailing twelve-month revenue and appeared to be executing well on its commercial strategy. Analysts had maintained a price target of $23.50 before the controversy, suggesting significant upside potential.
As investigations proceed, investors will be watching for several key developments: any formal inquiries from the Securities and Exchange Commission, additional analyst commentary, and most importantly, ADMA's ability to provide concrete evidence refuting the channel stuffing allegations. The company's next earnings report and any subsequent guidance will likely prove critical in determining whether the stock can recover from this dramatic sell-off.